|
1.Wobus, A.M. and K.R. Boheler, Embryonic stem cells: prospects for developmental biology and cell therapy. Physiol Rev, 2005. 85: p. 635-78. 2.Thomson, J.A., et al., Embryonic stem cell lines derived from human blastocysts. Science, 1998. 282: p. 1145-47. 3.Takahashi, K. and S. Yamanaka, Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 2006. 126: p. 663-76. 4.Takahashi, K. and S. Yamanaka, A decade of transcription factor-mediated reprogramming to pluripotency. Nat Rev Mol Cell Biol, 2016. 17: p.183-93. 5.Shi, Y., et al., Induced pluripotent stem cell technology: a decade of progress. Nat Rev Drug Discovery, 2017. 16: p. 115-30. 6.Kimbrel, E.A. and R. Lanza, Current status of pluripotent stem cells: moving the first therapies to the clinic. Nat Rev Drug Discovery, 2015. 14: p. 681-92. 7.Trounson, A. and C. McDonald, Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell, 2015. 17: p. 11-22. 8.Mandai, M., et al., Autologous induced stem-cell-derived retinal cells for macular degeneration. N Engl J Med, 2017. 376: p. 1038-46. 9.Cyranoski, D., Japanese man is first to receive ‘reprogrammed’ stem cells from another person. Nature, 2017.21730. 10.Trounson, A. and N.D. DeWitt, Pluripotent stem cells progressing to the clinic. Nat Rev Mol Cell Biol, 2016. 17: p. 194-200. 11.Tucker, B.A., et al., Duplication of TBK1 stimulates autophagy in iPSC-derived retinal cells from a patient with normal tension glaucoma. J Stem Cell Res Ther, 2014. 3: p. 161-. 12.Lee, G., et al., Large-scale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression. Nat Biotech, 2012. 30: p. 1244-48. 13.Li, L., et al., Human embryonic stem cells possess immune-privileged properties. Stem Cells, 2004. 22: p. 448-56. 14.Drukker, M., et al., Human embryonic stem cells and their differentiated derivatives are less susceptible to immune rejection than adult cells. Stem Cells, 2006. 24: p. 221-9. 15.Bonde, S., K.M. Chan, and N. Zavazava, ES-cell derived hematopoietic cells induce transplantation tolerance. PLoS One, 2008. 3: p. e3212. 16.Robertson, N.J., et al., Embryonic stem cell-derived tissues are immunogenic but their inherent immune privilege promotes the induction of tolerance. Proc Natl Acad Sci U S A, 2007. 104: p. 20920-5. 17.Chen, H.F., et al., Characteristic expression of major histocompatibility complex and immune privilege genes in human pluripotent stem cells and their derivatives. Cell Transplant, 2015. 24: p. 845-64. 18.Bonde, S. and N. Zavazava, Immunogenicity and engraftment of mouse embryonic stem cells in allogeneic recipients. Stem Cells, 2006. 24: p. 2192-201. 19.Janeway, C.A., et al., Immunobiology: The Immune System in Health and Disease. 5th edition. New York: Garland Science; 2001. The major histocompatibility complex and its functions. 20.Swijnenburg, R.J., et al., In vivo imaging of embryonic stem cells reveals patterns of survival and immune rejection following transplantation. Stem Cells Dev. 2008, 17: p. 1023-29. 21.Taylor, C.J., et al., Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching. Lancet. 2005, 366: p. 2019-25. 22.Chung, Y.G., et al., Human somatic cell nuclear transfer using adult cells. Cell Stem Cell, 2014. 14: p. 777-80. 23.Tachibana, M., et al., Human embryonic stem cells derived by somatic cell nuclear transfer. Cell, 2013. 153: p. 1228-38. 24.Deuse, T., et al., SCNT-derived ESCs with mismatched mitochondria trigger an immune response in allogeneic hosts. Cell Stem Cell, 2015. 16: p.33-38. 25.Guha, P., et al., Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells. Cell Stem Cell, 2013. 12: p. 407-12. 26.Zhao, T., et al., Immunogenicity of induced pluripotent stem cells. Nature, 2011. 474: p. 212-5. 27.Araki, R., et al., Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature, 2013. 494: p. 100-4. 28.Merling, R.K., et al., Transgene-free iPSCs generated from small volume peripheral blood nonmobilized CD34+ cells. Blood, 2013. 121: p. e98- 107. 29.Jonathan, D.P., et al., Regulation of immune responses by mTOR. Annu Rev Immunol. 2012, 30: p. 39-68. 30.Pollizzi, K.N. and J.D. Powell, Regulation of T cells by mTOR: the known knowns and the known unknowns. Trends Immunol, 2015. 36: p. 13-20. 31.Weichhart, T., M. Hengstschlager, and M. Linke, Regulation of innate immune cell function by mTOR. Nat Rev Immunol, 2015. 15: p. 599-614. 32.Sathaliyawala, T., et al., Mammalian target of rapamycin controls dendritic cell development downstream of Flt3 ligand signaling. Immunity, 2010. 33: p. 597-606. 33.Chen, H.F., et al., Derivation, characterization and differentiation of human embryonic stem cells: comparing serum-containing versus serum-free media and evidence of germ cell differentiation. Hum Reprod, 2007. 22: p. 567-77. 34.Huang, H.P., et al., Factors from human embryonic stem cell-derived fibroblast-like cells promote topology-dependent hepatic differentiation in primate embryonic and induced pluripotent stem cells. J Biol Chem, 2010. 285: p. 33510-9. 35.Burridge, P.W., et al., A universal system for highly efficient cardiac differentiation of human induced pluripotent stem cells that eliminates interline variability. PLoS ONE, 2011. 6: p. e18293. 36.Chen, H.F., et al., A reduced oxygen tension (5%) is not beneficial for maintaining human embryonic stem cells in the undifferentiated state with short splitting intervals. Hum Reprod, 2009. 24: p. 71-80. 37.Chen, H.F., et al., Novel autogenic feeders derived from human embryonic stem cells (hESCs) support an undifferentiated status of hESCs in xeno-free culture conditions. Hum Reprod, 2009. 24: p. 1114-25. 38.Ezashi, T., P. Das, and R.M. Roberts, Low O2 tensions and the prevention of differentiation of hES cells. Proc Natl Acad Sci U S A, 2005. 102: p.4783-8. 39.Mo, C.F., et al., Loss of non-coding RNA expression from the DLK1-DIO3 imprinted locus correlates with reduced neural differentiation potential in human embryonic stem cell lines. Stem Cell Res Ther, 2015. 6: p. 1. 40.Livak, K.J. and T.D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)). Method. Methods, 2001. 25: p. 402-8. 41.Lan, C.W., et al., Functional microarray analysis of differentially expressed genes in granulosa cells from women with polycystic ovary syndrome related to MAPK/ERK signaling. Sci Rep, 2015. 5: p. 14994. 42.Huang, H.P., et al., Epithelial cell adhesion molecule (EpCAM) complex proteins promote transcription factor-mediated pluripotency reprogramming. J Biol Chem, 2011. 286: p. 33520-32. 43.Yu, C.W., et al., Dual role of fatty acid-binding protein 5 on endothelial cell fate: a potential link between lipid metabolism and angiogenic responses. Angiogenesis, 2016. 19: p. 95-106. 44.Eisen, M.B., et al., Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A, 1998. 95: p. 14863-8. 45.Ortutay, C. and M. Vihinen, Immunome knowledge base (IKB): an integrated service for immunome research. BMC Immunol, 2009. 10: p. 3. 46.Mostoslavsky, G., et al., Efficiency of transduction of highly purified murine hematopoietic stem cells by lentiviral and oncoretroviral vectors under conditions of minimal in vitro manipulation. Mol Ther, 2005. 11: p. 932-40. 47.Wan, Y.Y., GATA3: a master of many trades in immune regulation. Trends Immunol, 2014. 35: p. 233-42. 48.Bhattacharya, S., et al., Prominin-1 is a novel regulator of autophagy in the human retinal pigment epithelium. Invest Ophthalmol Vis Sci, 2017. 58: p. 2366-87. 49.Fang, W., et al., Identification and activation of TLR4-mediated signaling pathways by alginate-derived guluronate oligosaccharide in RAW264.7 macrophages. Sci Rep, 2017. 7: p.1663-1675. 50.Zhu, M., et al., Alpha-fetoprotein activates AKT/mTOR signaling to promote CXCR4 expression and migration of hepatoma cells. Oncoscience, 2015. 2: p. 59-70. 51.Chang, J., et al., MyD88 is essential to sustain mTOR activation necessary to promote T helper 17 cell proliferation by linking IL-1 and IL-23 signaling. Proc Natl Acad Sci USA, 2013. 110: p. 2270-75. 52.Su, X., et al., Interferon-r regulates cellular metabolism and mRNA translation to potentiate macrophage activation. Nature Immunol, 2015. 16: p. 838-49. 53.Abhinand, C.S., et al., VEGF-A/VEGFR2 signaling network in endothelial cells relevant to angiogenesis. J Cell Commun Signal, 2016. 10: p. 347-54. 54.Paterson, Y.Z., et al., Equine mesenchymal stromal cells and embryo-derived stem cells are immune privileged in vitro. Stem Cell Res Ther, 2014. 5: p. 90. 55.Magliocca, J.F., I.K. Held, and J.S. Odorico, Undifferentiated murine embryonic stem cells cannot induce portal tolerance but may possess immune privilege secondary to reduced major histocompatibility complex antigen expression. Stem Cells Dev, 2006. 15: p. 707-17. 56.Menard, C., et al., Transplantation of cardiac-committed mouse embryonic stem cells to infarcted sheep myocardium: a preclinical study. Lancet, 2005. 366: p. 1005-12. 57.Boyd, A.S., et al., Concise review: Immune recognition of induced pluripotent stem cells. Stem Cells, 2012. 30: p. 797-803. 58.Moulding, D.A., et al., Actin cytoskeletal defects in immunodeficiency. Immunol Rev, 2013. 256: p. 282-99. 59.Xie, X.H., et al., Post-transcriptional CD59 gene silencing by siRNAs induces enhanced human T lymphocyte response to tumor cell lysate-loaded DCs. Cell Immunol, 2012. 274: p1-11. 60.Tanaka, T., et al., IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol, 2014. 6: a016295. 61.Camby, I., et al., Galectin-1: a small protein with major functions. Glycobiology, 2006. 16: p. 137-57. 62.Jersmann, H.P.A., Time to abandon dogma: CD14 is expressed by non-myeloid lineage cells. Immunol and cell biol, 2005. 83: p.462-67. 63.Magister, S. and J. Kos, Cystains in immune system. J Cancer, 2013. 4: p.45-56. 64.Ryter, S.W., J. Alam and A.M.K. Choi, Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol Rev, 2006. 86: p.583-650. 65.Abumaree, M., et al., Immunosuppressive properties of mesenchymal stem cells. Stem Cell Rev and Rep, 2012. 8: p. 375-92. 66.Cesari, M., M. Pahor, and R.A. Incalzi, Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions. Cardiovasc Ther, 2012. 28: p. 72-91. 67.Yamagami, S., et al., Effects of TGF-β2 on immune response-related gene expression profiles in the human corneal endothelium. Immunol and Microbiol, 2004. 45: p. 515-529. 68.Dunn, S., et al., The lectin-like oxidized low-density-lipoprotein receptor: a pro-inflammatory factor in vascular disease. Biochem J, 2008. 409: p. 349-55. 69.Ponticelli, C. and H.J. Anders, Thrombospondin immune regulation and kidney. Nephrol Dial Transplant, 2017, gfw431. doi: 10.1093/ndt/gfw431. 70.Zobalova, R., et al., The potential role of CD133 in immune surveillance and apoptosis: a mitochondrial connection? Antioxidant & Redox Signaling, 2011. 15: p. 2989-3002. 71.Corbeil, D., C.A. Fargeas, and J. Jaszai, CD133 might be a pan marker of epithelial cells with dedifferentiation capacity. Proc Natl Acad Sci U S A, 2014. 111: p. 1451-2. 72.Guerrini, M.M. and H. Takayanagi, The immune system, bone and RANKL. Arch Biochem Biophys, 2014. 561: p. 118-23. 73.Sims, J.E. and D.E. Smith, The IL-1 family: regulators of immunity. Nat Rev Immunol, 2010. 10: p.89-102. 74.Zhang, J., et al., Lack of MD2 expression in human corneal epithelia cells is an underlying mechanism of lipopolysaccharide (LPS) unresponsiveness. Immunol Cell Biol, 2009. 87: p. 141-48. 75.Liu, X.Y., et al., IFN-induced TPR protein IFIT3 potentiates antiviral signaling by bridging MAVS and TBK1. J Immunol, 2011. 187: p. 2559-68. 76.Ling, W., et al., Mesenchymal stem cells use IDO to regulate immunity in tumor microenvironment. Cancer Res, 2014. 74: p. 1576-87. 77.Manning, B.D. and L.C. Cantley, AKT/PKB signaling: navigating downstream. Cell, 2007. 129: p. 1261-74. 78.Dibble, C.C., and B.D. Manning, Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat Cell Biol, 2013. 15: p. 555-64. 79.Lee, K.W., et al., Rapamycin promotes the osteoblastic differentiation of human embryonic stem cells by blocking the mTOR pathway and stimulating the BMP/Smad pathway. Stem Cells Dev, 2010. 19: p. 557-68. 80.Singha, U.K., et al., Rapamycin inhibits osteoblast proliferation and differentiation in MC3T3-E1 cells and primary mouse bone marrow stromal cells. J Cell Biochem, 2008. 103: p. 434-46. 81.Ferrer, I.R., K. Araki, and M.L. Ford, Paradoxical aspects of rapamycin immunobiology in transplantation. Am J Transplant, 2011. 11: p. 654-9. 82.Zheng, Y., et al., A role for mammalian target of rapamycin in regulating T cell activation versus anergy. J Immunol, 2007. 178: p. 2163-70. 83.Murray, P.J., et al., Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity, 2014. 41: p. 14-20. 84.Schlitzer, A., et al., Identification of cDC1- and cDC2-committed DC progenitors reveals early lineage priming at the common DC progenitor stage in the bone marrow. Nature Immunol, 2015. 16: p. 718-28. 85.Theisen, D. and K. Murphy, The role of cDC1s in vivo: CD8 T cell priming through cross-presentation [version 1; referee: 3 approved]. F1000Research. 2017. 6 (F1000 Faculty Rev): 98. 86.Elghetany, M.T. and J. Patel, Assessment of CD24 expression on bone marrow neutrophilic granulocytes: CD24 is a marker for the myelocytic stage of development. Am J Hematol, 2002. 71: p. 348-9. 87.Liu, J.Q., et al., CD24 on the resident cells of the central nervous system enhances experimental autoimmune encephalomyelitis. J Immunol, 2007. 178: p. 6227-35. 88.Wilson, B.J., Dose GATA3 act in tissue-specific pathways? A meta-analysis-based approach. J Carcinog, 2008. 7: p. 6. 89.Radtke, F., H.R. MacDonald, and F. Tacchini-Cottier, Regulation of innate and adaptive immunity by Notch. Nat Rev Immunol, 2013. 13: p. 427-37. 90.Hernández-Hoyos, G., et al., GATA-3 expression is controlled by TCR signals and regulates CD4/CD8 differentiation. Immunity, 2003. 19: p. 83-94. 91.Pandolfi, P.P., et al., Targeted disruption of the GATA3 gene causes severe abnormalities in the nervous system and in fetal liver haematopoiesis. Nat Genet, 1995. 11: p. 40-4. 92.O''Garra, A. and L. Gabryšová, Correction: Transcription Factors Directing Th2 Differentiation: Gata-3 Plays a Dominant Role. J Immunol, 2016. 197: p. 4504. 93.Ting, C.N., et al., Transcription factor GATA-3 is required for development of the T-cell lineage. Nature, 1996. 384: p. 474-8. 94.Sakaguchi, S., et al., Regulatory T cells and immune tolerance. Cell, 2008. 133: p. 775-87. 95.Wohlfert, E.A., et al., GATA3 controls Foxp3(+) regulatory T cell fate during inflammation in mice. J Clin Invest, 2011. 121: p. 4503-15. 96.Wang, Y., M.A. Su, and Y.Y. Wan, An essential role of the transcription factor GATA-3 for the function of regulatory T cells. Immunity, 2011. 35: p. 337-48. 97.Song, H., et al., Critical role for GATA3 in mediating Tie2 expression and function in large vessel endothelial cells. J Biol Chem, 2009. 284: p. 29109-24. 98.Lim, K.C., et al., Gata3 loss leads to embryonic lethality due to noradrenaline deficiency of the sympathetic nervous system. Nat Genetics, 2000. 25: p. 209-12. 99.Takaku, M., et al., GATA3-dependent cellular reprogramming requires activation-domain dependent recruitment of a chromatin remodeler. Genome Biol, 2016. 17: p. 36-51. 100.Yan, W., et al., GATA3 inhibits breast cancer metastasis through the reversal of epithelial-mesenchymal Transition. J. Biol Chem, 2010. 285: p. 14042-51. 101.Feng, Y., et al., CD103 expression is required for destruction of pancreatic islet allografts by CD8+ T cells. J Exp Med, 2002. 196: p. 877-86. 102.Allison, T.L., Immunosuppressive Therapy in Transplantation. Nurs Clin North Am, 2016. 51: p. 107-20. 103.Rong, Z., et al., An effective approach to prevent immune rejection of human ESC-derived allografts. Cell Stem Cell, 2014. 14: p. 121-30. 104.Sontag, C.J., et al., Immunosuppressants affect human neural stem cells in vitro but not in an in vivo model of spinal cord injury. Stem Cells Transl Med, 2013. 2: p. 731-44.
|